Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma
Open Access
- 29 July 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (7), e23062
- https://doi.org/10.1371/journal.pone.0023062
Abstract
Aberrant expression of the progenitor marker Neuron-glia 2 (NG2/CSPG4) or melanoma proteoglycan on cancer cells and angiogenic vasculature is associated with an aggressive disease course in several malignancies including glioblastoma multiforme (GBM) and melanoma. Thus, we investigated the mechanism of NG2 mediated malignant progression and its potential as a therapeutic target in clinically relevant GBM and melanoma animal models. Xenografting NG2 overexpressing GBM cell lines resulted in increased growth rate, angiogenesis and vascular permeability compared to control, NG2 negative tumours. The effect of abrogating NG2 function was investigated after intracerebral delivery of lentivirally encoded shRNAs targeting NG2 in patient GBM xenografts as well as in established subcutaneous A375 melanoma tumours. NG2 knockdown reduced melanoma proliferation and increased apoptosis and necrosis. Targeting NG2 in two heterogeneous GBM xenografts significantly reduced tumour growth and oedema levels, angiogenesis and normalised vascular function. Vascular normalisation resulted in increased tumour invasion and decreased apoptosis and necrosis. We conclude that NG2 promotes tumour progression by multiple mechanisms and represents an amenable target for cancer molecular therapy.Keywords
This publication has 39 references indexed in Scilit:
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastomaProceedings of the National Academy of Sciences of the United States of America, 2011
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- A reproducible brain tumour model established from human glioblastoma biopsiesBMC Cancer, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signalingOncogene, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implicationsFrontiers in Bioscience-Landmark, 2000
- NG2 expression in MLL rearranged acute myeloid leukaemia is restricted to monoblastic casesBritish Journal of Haematology, 1999
- Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cellsJournal of Cellular Physiology, 1998
- Measurement of vascular volume fraction and blood‐tissue permeability constants with a pharmacokinetic model: Studies in rat muscle tumors with dynamic Gd‐DTPA enhanced MRIMagnetic Resonance in Medicine, 1994